Cambridge Healthtech Institute’s 3rd Annual
Next-Gen Degraders: Glues & Conjugates
11-12 November 2026
There is a wave of innovations driving the design and development of new degrader modalities to get the desired therapeutic outcomes. Cambridge Healthtech Institute’s conference on Next-Gen Degraders: Glues & Conjugates continues to track the progress in designing new proteolysis-targeting chimeras (PROTACs) and molecular glues, while shedding light on novel modalities like degrader-antibody conjugates (DACs) seeking out challenging drug targets. It brings together chemists, biologists, computational and PKPD experts to discuss how new chemistries can be utilised, cellular pathways exploited, screening tools and assays leveraged, and predictive models tapped into, for achieving targeted protein degradation.
Through focused talks, case studies, and interactive panels, pharma R&D leaders, biotech founders, academic innovators, and investors will gain insight into design challenges and translational bottlenecks.
Coverage will include, but is not limited to:
- Novel modalities: PROTACs and molecular glues; degrader-antibody conjugates
- Innovative degradation chemistries: covalent chemistry, induced proximity, linker design
- Structural and mechanistic studies: biochemical, phenotypic, cell-based screening
- AI/ML models for target discovery, drug design, lead optimisation of degraders
- Pursuing novel degradation pathways: new E3 ligases, going beyond E3 ligases
- Optimising ADME/DMPK: improving oral bioavailability, tissue specificity, stability
- Advances in targeted delivery, minimising off-target and safety concerns
- Pursuing challenging drug targets: transcription factors, extracellular targets, RNA
- Non-oncology applications: immunology/autoimmune, inflammation, neurodegeneration
Who Should Attend:
- Medicinal chemists driving the design and synthesis of next-generation drug-like molecules
- Discovery scientists advancing programs through hit-to-lead, lead optimisation, and target engagement
- Assay developers and screening specialists seeking innovative approaches to uncover high-quality hits and leads
- Computational scientists applying AI-driven drug design, virtual screening, and integrated DMTA workflows
- Chemists and biologists exploring tools and strategies for evaluating emerging drug modalities
- AI/ML and data science experts building and modelling novel chemical entities
- Scientists focused on developability, including prediction and optimisation of drug-like properties
The deadline for priority consideration is 10 April 2026
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: